HUM Humana Inc.

Humana and Monogram Health Announce Expansion of Comprehensive Kidney Care Program

Humana and Monogram Health are pleased to announce a significant expansion, extending member access to in-home treatment for kidney disease and its underlying causes. Eligible Humana Medicare Advantage members in Alabama, Louisiana, Mississippi, Tennessee, and now Georgia with chronic kidney disease (CKD) and end-stage kidney disease (ESKD) will have access to Monogram’s evidence-based nephrology and multispecialty value-based care in the comfort of their homes.

This press release features multimedia. View the full release here:

Value-based care focuses on the collaboration and coordination of all aspects of a patient’s care, and this expansion enables earlier interventions to a larger population in existing markets while also reaching new patients statewide in Georgia, highlighting a strong commitment to quality, in-home kidney care that addresses the needs of traditionally underserved populations.

"Providing access to quality care for our Medicare Advantage members with complex health conditions is crucial," said Alan Stewart, President of Humana's Medicare East Division. "Our collaboration with Monogram enables us to enhance support for our members with chronic kidney disease and end-stage kidney disease to help improve health outcomes."

“We don’t just treat the manifestation of the disease, but the conditions that cause kidney disease, like hypertension, diabetes, and metabolic disorders,” said Michael Uchrin, Chief Executive Officer and Co-Founder of Monogram Health. “It is our privilege to work together with Humana to deliver quality, specialist-driven care to their members where they are most comfortable – in their homes.”

Chronic kidney disease affects approximately 37 million Americans, many of whom also struggle with multiple chronic conditions like diabetes, high blood pressure, and heart disease. A majority of CKD patients have never seen a nephrologist, revealing a considerable deficiency in specialized care access. This is particularly relevant in the states Monogram covers through this agreement with Humana – as nearly 15% of the Medicare aged population in Alabama, Tennessee, and Louisiana have chronic kidney disease, which are some of the highest prevalence rates in the country.

About Humana

Humana Inc. is committed to putting health first – for our teammates, our customers, and our company. Through our Humana insurance services, and our CenterWell health care services, we strive to make it easier for the millions of people we serve to achieve their best health – delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare, Medicaid, families, individuals, military service personnel, and communities at large. Learn more about what we offer at and at .

About Monogram Health

Monogram Health is the leading value-based multispecialty provider of in-home evidence-based care and benefit management services for patients living with polychronic conditions, notably chronic kidney and end-stage kidney disease. The company deploys an innovative in-home care delivery model and technology-driven array of evidence-based clinical services, including complex case and disease management, utilization management, and medication therapy management to transform the way health care is delivered for those with polychronic conditions. This innovative model of care has been shown to dramatically improve patient outcomes and quality of life while reducing medical costs across the health care continuum. Based in Nashville, Tennessee, and privately held by Frist Cressey Ventures, Norwest Venture Partners, TPG Capital, as well as other leading strategic and financial investors, Monogram Health has numerous value-based partnerships with leading health plans and risk-bearing providers to care for patients across 36 states and all insurance products. To learn more about Monogram Health, ranked 2024’s No. 3 fastest growing private company in the United States, please visit .

Disclaimer: Other providers are available in the Humana network. Provider may also contract with other plan sponsors.

Y0040_GCHMKZAEN_C

EN
13/02/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Humana Inc.

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: May 17, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Humana Inc: 1 director

Two Directors at Humana Inc bought 7,133 shares at between 0.000USD and 229.247USD. The significance rating of the trade was 76/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last...

Moody’s Ratings rates Humana’s senior notes Baa2; outlook negative

New York , March 3, 2025 – Moody's Ratings (Moody's) has assigned a Baa2 senior unsecured debt rating to Humana Inc.'s (Humana, NYSE: HUM, senior debt at Baa2) planned issuance of up to $1.25 billion of senior unsecured notes due in 2035 and 2055. The net proceeds of this transaction are for general...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch